MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a ...

FDA unveils a priority voucher program to accelerate drug reviews for national priorities, using a team-based review model.

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase ...

This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

How can early decisions in cell and gene therapy clinical development impact downstream progress toward commercialization and ...

Koby Baranes, PhD, head of science at Clock Bio, cautions, “Aging is not yet fully understood and existing models often fail ...